Potential use of n-3 PUFAs to prevent oxidative stress-derived ototoxicity caused by platinum-based chemotherapy

Simple item page
dc.coverageDOI: 10.1016/j.freeradbiomed.2020.07.035
dc.creatorCortés Fuentes, Ignacio A.
dc.creatorBurotto, Mauricio
dc.creatorRetamal, Mauricio A.
dc.creatorFrelinghuysen, Michael
dc.creatorCaglevic, Christian
dc.creatorGormaz, Juan G.
dc.date2020
dc.date.accessioned2025-11-18T19:52:10Z
dc.date.available2025-11-18T19:52:10Z
dc.description<p>Platinum-based compounds are widely used for the treatment of different malignancies due to their high effectiveness. Unfortunately, platinum-based treatment may lead to ototoxicity, an often-irreversible side effect without a known effective treatment and prevention plan. Platinum-based compound-related ototoxicity results mainly from the production of toxic levels of reactive oxygen species (ROS) rather than DNA-adduct formation, which has led to test strategies based on direct ROS scavengers to ameliorate hearing loss. However, favorable clinical results have been associated with several complications, including potential interactions with chemotherapy efficacy. To understand the contribution of the different cytotoxic mechanisms of platinum analogues on malignant cells and auditory cells, the particular susceptibility and response of both kinds of cells to molecules that potentially interfere with these mechanisms, is fundamental to develop innovative strategies to prevent ototoxicity without affecting antineoplastic effects. The n-3 long-chain polyunsaturated fatty acids (n-3 PUFAs) have been tried in different clinical settings, including with cancer patients. Nevertheless, their use to decrease cisplatin-induced ototoxicity has not been explored to date. In this hypothesis paper, we address the mechanisms of platinum compounds-derived ototoxicity, focusing on the differences between the effects of these compounds in neoplastic versus auditory cells. We discuss the basis for a strategic use of n-3 PUFAs to potentially protect auditory cells from platinum-derived injury without affecting neoplastic cells and chemotherapy efficacy.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/3ad07663-a2f8-4d8c-8311-d3fc5d88ce33
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/57582
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.160 (2020) date: 2020-11-20 p.263-276
dc.subjectAntioxidants
dc.subjectCisplatin
dc.subjectHearing loss
dc.subjectn-3 PUFAs
dc.subjectOmega-3
dc.subjectOtoprotection
dc.subjectOtotoxicity
dc.subjectPlatinum-analogue
dc.subjectSDG 3 - Good Health and Well-being
dc.titlePotential use of n-3 PUFAs to prevent oxidative stress-derived ototoxicity caused by platinum-based chemotherapyeng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
PURE